Montague, Brian T.
Wipperman, Matthew F.
Chio, Erica
Crow, Rowena
Hooper, Andrea T.
O’Brien, Meagan P.
Simões, Eric A. F.
Funding for this research was provided by:
Regeneron Pharmaceuticals (0000-COV-CES-2053)
Article History
Received: 25 February 2022
Accepted: 24 August 2022
First Online: 2 September 2022
Competing interests
: This study received funding from Regeneron Pharmaceuticals as an investigator-initiated study, with funding from Regeneron Pharmaceuticals to Eric Simoes PI and Brian Montague Co-Investigator Grant No. 0000-COV-CES-2053. Final decisions regarding study design, implementation, data analysis and manuscript preparation were made by the principal investigator and co-investigator. Coauthors affiliated with Regeneron Pharmaceuticals provided collaborative assistance with coordination of laboratory testing, data review and analysis, and review of the final manuscript. M.F.W., A.T.H., S.C.H., F.E., L.H., S.L., J.D.H. and M.P.O. are current employees and stockholders of Regeneron Pharmaceuticals. A.T.H. is a prior employee and stockholder for Pfizer, Inc. All authors declare no other competing interests.